{
    "2021-07-17": [
        [
            {
                "time": "",
                "original_text": "沃森生物：公司目前已有进入临床研究和注册申报阶段的各产品均在按计划正常推进相关工作",
                "features": {
                    "keywords": [
                        "临床研究",
                        "注册申报",
                        "正常推进"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司H股发行事宜已经公司股东大会审议并通过，已收到中国证监会出具的《行政许可申请受理单》，相关工作在持续推进中",
                "features": {
                    "keywords": [
                        "H股发行",
                        "股东大会",
                        "证监会",
                        "持续推进"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "资本市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司新冠mRNA疫苗临床试验的各项工作在正常推进中",
                "features": {
                    "keywords": [
                        "新冠mRNA疫苗",
                        "临床试验",
                        "正常推进"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗研发"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "沃森生物：公司13价肺炎结合疫苗生产、批签发和销售工作均正常开展",
                "features": {
                    "keywords": [
                        "13价肺炎结合疫苗",
                        "生产",
                        "批签发",
                        "销售",
                        "正常开展"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗销售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}